+

WO2008115597A3 - Cytokine muteins and methods for enhancing immune responses in mammals - Google Patents

Cytokine muteins and methods for enhancing immune responses in mammals Download PDF

Info

Publication number
WO2008115597A3
WO2008115597A3 PCT/US2008/003803 US2008003803W WO2008115597A3 WO 2008115597 A3 WO2008115597 A3 WO 2008115597A3 US 2008003803 W US2008003803 W US 2008003803W WO 2008115597 A3 WO2008115597 A3 WO 2008115597A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mammals
immune responses
cytokine
enhancing immune
Prior art date
Application number
PCT/US2008/003803
Other languages
French (fr)
Other versions
WO2008115597A2 (en
Inventor
Mark Douglas Howell
Original Assignee
Cytologic Inc
Mark Douglas Howell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytologic Inc, Mark Douglas Howell filed Critical Cytologic Inc
Publication of WO2008115597A2 publication Critical patent/WO2008115597A2/en
Publication of WO2008115597A3 publication Critical patent/WO2008115597A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided are cytokine muteins and methods of use thereof for increasing an immune response in a mammal to treat various chronic diseases. Also provided is an adsorbent matrix, composed of an inert, biocompatible substrate joined covalently to one or more cytokine muteins, that is capable of specifically binding to soluble cytokine receptors.
PCT/US2008/003803 2007-03-21 2008-03-21 Cytokine muteins and methods for enhancing immune responses in mammals WO2008115597A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91916607P 2007-03-21 2007-03-21
US60/919,166 2007-03-21

Publications (2)

Publication Number Publication Date
WO2008115597A2 WO2008115597A2 (en) 2008-09-25
WO2008115597A3 true WO2008115597A3 (en) 2009-01-15

Family

ID=39766687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003803 WO2008115597A2 (en) 2007-03-21 2008-03-21 Cytokine muteins and methods for enhancing immune responses in mammals

Country Status (1)

Country Link
WO (1) WO2008115597A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US20030003135A1 (en) * 2001-06-28 2003-01-02 Leung Jeffrey C. Article for drug delivery and methods of making and using same
US20030021845A1 (en) * 1999-11-29 2003-01-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Gastroretentive controlled release pharmaceutical dosage forms
US20040219096A1 (en) * 2002-12-31 2004-11-04 Rene De Waal Malefyt Uses of mammalian cytokine; related reagents
US20050100543A1 (en) * 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US20030021845A1 (en) * 1999-11-29 2003-01-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Gastroretentive controlled release pharmaceutical dosage forms
US20030003135A1 (en) * 2001-06-28 2003-01-02 Leung Jeffrey C. Article for drug delivery and methods of making and using same
US20040219096A1 (en) * 2002-12-31 2004-11-04 Rene De Waal Malefyt Uses of mammalian cytokine; related reagents
US20050100543A1 (en) * 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies

Also Published As

Publication number Publication date
WO2008115597A2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007024715A3 (en) Dual variable domain immunoglobin and uses thereof
SG10201608268RA (en) Human antibodies that bind cxcr4 and uses thereof
WO2008039361A3 (en) Method for enhancing immune responses in mammals
SG165322A1 (en) Engineered anti-il-23 antibodies
HK1222870A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r il-22 il-22r
WO2008024188A3 (en) Dual variable domain immunoglobulin and uses thereof
WO2006125962A3 (en) T cell receptors which specifically bind to vygfvracl-hla-a24
WO2012006490A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2006015385A3 (en) Anti-angiogenic peptides and methods of use thereof
EP1977746B8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2006077471A3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
EP2447280A3 (en) VEGF analogs and methods of use
EP2133365A3 (en) Compositions and methods for the treatment of infections and tumors
WO2010141596A3 (en) Chemical proteomic assay for optimizing drug binding to target proteins
WO2008094208A3 (en) Protein kinase targeted therapeutics
IL221006A0 (en) Pharmaceutical composition, kits and combinations comprising roflumilast and/of its n-oxide derivative together with other component active in treating diabetes
ZA200904657B (en) Human antibodies that bind CD70 and uses thereof
AU2007309650A8 (en) Soluble TNF receptors and their use in treatment of disease
AU2006223217A1 (en) Maize seed with synergistically enhanced lysine content
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2009055074A3 (en) Erbb2 binding proteins and use thereof
WO2009121847A3 (en) Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727099

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08727099

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载